Chat With UsChat With UsBy Fabiha Imtiyaz • 30 April 2026
Houston, Texas | April 30, 2026 – The Future Biotech Expo 2026 will take place on June 2–3 in Houston, convening global leaders across biotechnology, pharmaceuticals, artificial intelligence, clinical research and investment for two days of high-impact discussions and strategic collaboration.
Sponsored and supported by the Texas Medical Center (TMC) as a key knowledge partner, the Expo is positioned at the heart of one of the world’s largest life sciences ecosystems, bringing together industry, academia and capital under one platform.
Ahead of the main conference, the Expo will host an exclusive Day Zero private networking session “Texas Connect” on June 1 at the TMC Innovation Building, designed for a curated group of C-suite executives, biotech founders, investors and senior industry leaders. This closed-door gathering will focus on high-value connections, strategic conversations and early-stage collaboration opportunities in an intimate setting.
The two-day conference agenda is built around the most critical themes shaping the future of biotechnology, including oncology innovation, AI-driven drug discovery, next-generation diagnostics, clinical trials and biotech investment strategies. The program opens with a dedicated spotlight on Texas’ biotech ecosystem, featuring leadership from TMC, CPRIT, THBI and BioHouston, reflecting the region’s growing influence in global life sciences.
A major highlight of the Expo is its deep focus on oncology and advanced therapeutics with participation from leading institutions such as MD Anderson Cancer Center and global pharmaceutical companies including Bristol Myers Squibb, Boehringer Ingelheim and the American Cancer Society. Sessions will explore breakthroughs in immunotherapy, CAR-T and CAR-NK cell therapies and innovative approaches to high-risk cancers. The Expo will also showcase the rapid digital transformation of biotech, with leaders from Roche, Novartis, Johnson & Johnson, Pfizer, Genmab and Parexel discussing how artificial intelligence, automation, and data are reshaping drug development, clinical trials and commercial strategy.
Further sessions will focus on diagnostics and precision medicine, with contributions from AstraZeneca, Illumina, Harvard T.H. Chan School of Public Health, Natera and Castle Biosciences, covering biomarker-driven trials, genomic diagnostics and next-generation tools in precision healthcare. The conference will also spotlight clinical trials and translational medicine, alongside patient-centric trial design and regulatory strategy, with participation from Sanofi, IQVIA and Merck.
A defining feature of the Expo is its strong investment and startup ecosystem focus, bringing together some of the world’s most active biotech investors. Confirmed participation includes J.P. Morgan, Capital Factory and IB Ventures- Saudi Arabia, among others. The event will create direct pathways for startups to engage with investors, gain visibility and explore funding and commercialization opportunities.
The Expo is expected to welcome 2500 + global participants, including biotech executives, researchers, investors, startups and policymakers, making it a truly international platform for collaboration and deal-making.
Confirmed speakers include senior leaders and experts such as:
…along with several other distinguished speakers representing global pharmaceutical companies, biotech innovators, academic institutions and leading investment firms.
In addition to conference sessions, the Future Biotech Expo 2026 will feature curated networking opportunities, Startup Acceleration Program and dedicated platforms for startups and innovators to connect with global stakeholders.
With its combination of high-level speakers, global investors and a forward-looking agenda, the Future Biotech Expo 2026 is set to position Houston as a key meeting point for the future of biotechnology innovation and investment.
Media Contact:
Fabiha Imtiyaz
Conference Producer
Future Biotech Expo | Maxpo Exhibitions Pvt. Ltd.